For example, recent work published in Nature Cancer revealed that inhibiting KDM6B epigenetically reprograms cytokine networks, shifting macrophages from immunosuppressive to immunostimulatory phenotypes and sensitizing gliomas to PD-1 checkpoint blockade. This evidence concerns the gene KDM6B and glioma.